Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.
The US regulator has come down surprisingly hard on biotech stock promotion schemes.